Literature DB >> 23428644

High-density lipoprotein subfractions--what the clinicians need to know.

Angela Pirillo1, Giuseppe Danilo Norata, Alberico Luigi Catapano.   

Abstract

Although the inverse relationship between plasma levels of high-density lipoprotein (HDL) and cardiovascular disease has been largely demonstrated, many observations have suggested that the assessment of HDL functionality might be more informative than a simple measurement of HDL-cholesterol plasma levels. HDLs are a class of structurally and functionally heterogeneous particles; in atherosclerosis-related diseases, changes in HDL subfraction levels and functions are frequently observed. Circulating levels of large HDL particles are decreased in dyslipidaemic conditions, while levels of small dense HDL particles are increased in patients with coronary heart disease. Furthermore, specific genetic defects in proteins involved in HDL metabolism significantly impact the distribution of HDL subpopulations. Finally, many drugs used for dyslipidaemia induce changes in HDL subfractions strictly related to cardiovascular disease. Although several methods exist to evaluate HDL subclass levels, most of them are not easily applicable in clinical practice, due to the costs and high variability. However, the possibility to measure the levels of specific HDL subfractions in patients with atherosclerosis-related diseases might help to better define their cardiovascular risk.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428644     DOI: 10.1159/000346463

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  34 in total

Review 1.  Novel concepts in HDL pharmacology.

Authors:  Alan T Remaley; Giuseppe D Norata; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2014-06-20       Impact factor: 10.787

Review 2.  HDL: to treat or not to treat?

Authors:  Angela Pirillo; Gianpaolo Tibolla; Giuseppe Danilo Norata; Alberico Luigi Catapano
Journal:  Curr Atheroscler Rep       Date:  2014-08       Impact factor: 5.113

Review 3.  High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus.

Authors:  Yi He; Vishal Kothari; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02       Impact factor: 8.311

Review 4.  Synthetic high-density lipoprotein-like nanoparticles as cancer therapy.

Authors:  Kaylin M McMahon; Linda Foit; Nicholas L Angeloni; Francis J Giles; Leo I Gordon; C Shad Thaxton
Journal:  Cancer Treat Res       Date:  2015

5.  Correlation between high density lipoprotein and monocyte subpopulations among stable coronary atherosclerotic heart disease patients.

Authors:  Rong-Hai Yang; Ying-Feng Liu; Xue-Jun Wang; Jian-Guang Liang; Jia-Chao Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 6.  High-density lipoproteins for the systemic delivery of short interfering RNA.

Authors:  Kaylin Marie McMahon; Colby Shad Thaxton
Journal:  Expert Opin Drug Deliv       Date:  2013-12-09       Impact factor: 6.648

7.  SCARB1 Gene Polymorphisms and HDL Subfractions in Coronary Artery Disease.

Authors:  Huseyin Ayhan; Uzay Gormus; Selim Isbir; Seda Gulec Yilmaz; Turgay Isbir
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

Review 8.  The role of high-density lipoprotein in the regulation of the immune response: implications for atherosclerosis and autoimmunity.

Authors:  Marisa Fernandes das Neves; Joana R Batuca; José Delgado Alves
Journal:  Immunology       Date:  2021-05-22       Impact factor: 7.215

Review 9.  Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?

Authors:  Susana Coimbra; Flávio Reis; Maria João Valente; Susana Rocha; Cristina Catarino; Petronila Rocha-Pereira; Maria Sameiro-Faria; Elsa Bronze-da-Rocha; Luís Belo; Alice Santos-Silva
Journal:  Biomedicines       Date:  2021-05-16

10.  Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women.

Authors:  Filipa Mascarenhas-Melo; Daniela Marado; Filipe Palavra; José Sereno; Álvaro Coelho; Rui Pinto; Edite Teixeira-Lemos; Frederico Teixeira; Flávio Reis
Journal:  Cardiovasc Diabetol       Date:  2013-04-09       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.